DocGo Q2 Loss Widens to $18M; Going Concern Doubt and Hicuity Merger Disclosed
DCGO sits 57% above its 52-week low of $0.451 on elevated volume (1.8× avg).
Summary
DocGo reported a wider Q2 loss, disclosed going concern doubt, and revealed a subsequent agreement to acquire Hicuity Health with significant debt assumption.
Key Events · Earnings and Guidance · DCGO
-
Q2 Loss Widens
Net loss of $18.0 million for Q2 2026, up from $13.3 million in Q2 2025. Six-month loss of $34.7 million versus $24.3 million a year earlier.
-
Cash Burn Accelerates
Unrestricted cash fell to $25.2 million as of June 30, 2026, from $51.0 million at December 31, 2025. Operating activities used $13.9 million in the first half.
-
Going Concern Doubt
Management discloses substantial doubt about the company's ability to continue as a going concern, citing ongoing operating losses and covenant non-compliance, but believes cost-reduction plans will alleviate the doubt.
-
Covenant Breach Unresolved
The company was not in compliance with its minimum liquidity covenant as of December 31, 2025, and discussions with the lender were still ongoing as of June 30, 2026.
Analysis · DCGO · Industrial Applications And Services
DocGo's Q2 2026 net loss widened to $18.0 million from $13.3 million a year earlier, and cash fell to $25.2 million from $51.0 million at year-end. Management states substantial doubt about its ability to continue as a going concern, though it believes cost-cutting plans will alleviate that doubt. The company also disclosed a subsequent agreement to acquire Hicuity Health for stock and debt assumption, adding up to $52 million in assumed debt and a $50 million term loan commitment. The filing confirms the company remains in covenant non-compliance with its lender and has until January 25, 2027 to regain Nasdaq compliance.
At the time of this filing, DCGO was trading at $0.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $70.1M. The 52-week trading range was $0.45 to $1.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.